Coya plans open-label extension of ALS trial, delays FTD study
Tweet Send to a Friend
Coya Therapeutics (NASDAQ: COYA) announced plans to initiate an open-label extension (OLE) of its Phase 2/3 ALSTARS trial evaluating COYA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




